February 2, 2021: Pfizer expects to sell around $15 billion in coronavirus vaccine doses this year, the company announced on Tuesday in releasing its fourth-quarter earnings.
The company’s Covid-19 vaccine, with BioNTech, was approved for emergency use in the U.S. for the first time. It forecast between $59.4 and $61.4 billion in revenue this year.
“As a company, we saw the culmination of Pfizer’s decade-long conversion into a pure-play, science and innovation-focused company,” Pfizer CEO Albert Bourla said in a press release.
Bourla added, “Right away, our ability to move quickly and utilize cutting-edge science to help address the world’s most important medical challenges was put to the test by the COVID-19 pandemic.”
Like other Covid-19 vaccine makers, Pfizer has been struggling to meet the demand for doses that will end the coronavirus pandemic.
Pfizer expects to deliver 200 million doses of its two-dose vaccine to the U.S. by July 31. It recently enlisted the help of French drugmaker Sanofi to help produce the shots.
On Tuesday, the company said it is “prepared to respond” if a COVID-19 variant demonstrates evidence of evading its vaccine.
In recent weeks, Dr. Anthony Fauci, including other U.S. health officials, are concerned regarding the vaccines on the market currently may not be effective in protecting the new contagious strains of the virus.
A company conducted a study that found the new Covid-19 strains found in the U.K. and South Africa had only a small impact on its effectiveness.
Still, A booster shot is being developed by Pfizers to protect from the new variants of the disease. Modified vaccines are also developed by Moderna and Novavax.
We provide the insights on leaders who are responsible for taking their organization to new heights, all the while bringing together a group of talented individuals.
September 26, 2023: On Monday, Japanese automaker Nissan revealed its dedication to transitioning to completely electric …
In an industry as competitive and fast-paced as Consumer Packaged Goods (CPG), standing out from the crowd requires innovation and adaptability. The cracks in the CPG supply chain were exposed long before the global pandemic struck, but the events of the past year only exacerbated the weaknesses.
Supply chain leaders, including VPs, often find themselves making bets with unknown financial consequences. Having started with largely infeasible plans generated by deterministic “one-number” planning systems, compounded by unexpected supply or demand disruptions, they are forced into last-minute adjustments to meet operational and financial goals.
Unsurprisingly, today’s supply chain faces numerous issues, including sustainability, technology, global economic and political instability, talent management, and supply chain resilience. Advanced forecasting algorithms and predictive analytics are used in supply chain management to help organizations of all sizes make better decisions by providing insights into what’s going on in their business at any given moment and predicting future trends.
Ensuring the right products are in the right place and at the right time is critical for companies also dealing with supply chain constraints and a high degree of variability. Uncertainty has become the name of the game and the only way to effectively optimize inventory through continuous, data-driven assessments, planning, and decision-making.
Food Huggers, a consumer brand that designs products to reduce waste at home, may be in an enviable position now but before they found Extensiv Order Manager, managing booming orders and staying on top of inventory was a huge operational challenge. The business has inventory spread across multiple geographically distributed warehouses, with orders received via multiple sales channels, including Shopify storefronts and Amazon.